BRIEF-Edgewise Receives U.S. FDA Fast Track Designation For Edg-5506 For The Treatment Of Individuals With Becker Muscular Dystrophy (Bmd)

1
1
Favorite

BRIEF-Edgewise Receives U.S. FDA Fast Track Designation For Edg-5506 For The Treatment Of Individuals With Becker Muscular Dystrophy (Bmd)

Reuters2021-08-16

Aug 16 (Reuters) - Edgewise Therapeutics Inc :

* EDGEWISE RECEIVES U.S. FDA FAST TRACK DESIGNATION FOR EDG-5506 FOR THE TREATMENT OF INDIVIDUALS WITH BECKER MUSCULAR DYSTROPHY $(BMD.UK)$

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（1）

JHx
·2021-08-16
Yeah
Reply
1
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2159221951?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-08-16 21:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2159221951","market":"us","top_or_hot":-1,"title":"BRIEF-Edgewise Receives U.S. FDA Fast Track Designation For Edg-5506 For The Treatment Of Individuals With Becker Muscular Dystrophy (Bmd)","media":"Reuters","content":"<html><body><p>Aug 16 (Reuters) - Edgewise Therapeutics Inc   :</p><p>   * EDGEWISE RECEIVES U.S. FDA FAST TRACK DESIGNATION FOR EDG-5506 FOR THE TREATMENT OF INDIVIDUALS WITH BECKER MUSCULAR DYSTROPHY <a href=\"https://laohu8.com/S/BMD.UK\">$(BMD.UK)$</a></p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Edgewise Receives U.S. FDA Fast Track Designation For Edg-5506 For The Treatment Of Individuals With Becker Muscular Dystrophy (Bmd)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Edgewise Receives U.S. FDA Fast Track Designation For Edg-5506 For The Treatment Of Individuals With Becker Muscular Dystrophy (Bmd)\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-16 21:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Aug 16 (Reuters) - Edgewise Therapeutics Inc   :   * EDGEWISE RECEIVES U.S. FDA FAST TRACK DESIGNATION FOR EDG-5506 FOR THE TREATMENT OF INDIVIDUALS WITH BECKER MUSCULAR DYSTROPHY $(BMD.UK)$Source ...</p>\n\n<a href=\"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EWTX","symbol_name":"Edgewise Therapeutics, Inc.","start_time":0,"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2159221951","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2159221951","pubTimestamp":1629119634,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Aug 16 (Reuters) - Edgewise Therapeutics Inc   :   * EDGEWISE RECEIVES U.S. FDA FAST TRACK DESIGNATI","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"EWTX":"Edgewise Therapeutics, Inc."},"translate_title":"Brief-Edgewise获得美国FDA的Edg-5506快速通道指定，用于治疗贝克尔肌营养不良(Bmd)患者","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EWTX":0.9},"content_text":"Aug 16 (Reuters) - Edgewise Therapeutics Inc   :   * EDGEWISE RECEIVES U.S. FDA FAST TRACK DESIGNATION FOR EDG-5506 FOR THE TREATMENT OF INDIVIDUALS WITH BECKER MUSCULAR DYSTROPHY $(BMD.UK)$Source text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[{"id":839300949,"gmtCreate":1629120871981,"gmtModify":1676529936658,"author":{"id":"3573821515865359","authorId":"3573821515865359","name":"JHx","avatar":"https://static.tigerbbs.com/54eb39bebd911124a59d7bf934977d25","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3573821515865359","authorIdStr":"3573821515865359"},"htmlText":"Yeah","listText":"Yeah","text":"Yeah","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/839300949","repostId":2159221951,"repostType":2,"repost":{"id":"2159221951","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1629119634,"share":"https://ttm.financial/m/news/2159221951?lang=&edition=fundamental","pubTime":"2021-08-16 21:13","market":"us","language":"en","title":"BRIEF-Edgewise Receives U.S. FDA Fast Track Designation For Edg-5506 For The Treatment Of Individuals With Becker Muscular Dystrophy (Bmd)","url":"https://stock-news.laohu8.com/highlight/detail?id=2159221951","media":"Reuters","summary":"Aug 16 (Reuters) - Edgewise Therapeutics Inc   :   * EDGEWISE RECEIVES U.S. FDA FAST TRACK DESIGNATI","content":"<html><body><p>Aug 16 (Reuters) - Edgewise Therapeutics Inc   :</p><p>   * EDGEWISE RECEIVES U.S. FDA FAST TRACK DESIGNATION FOR EDG-5506 FOR THE TREATMENT OF INDIVIDUALS WITH BECKER MUSCULAR DYSTROPHY <a href=\"https://laohu8.com/S/BMD.UK\">$(BMD.UK)$</a></p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Edgewise Receives U.S. FDA Fast Track Designation For Edg-5506 For The Treatment Of Individuals With Becker Muscular Dystrophy (Bmd)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Edgewise Receives U.S. FDA Fast Track Designation For Edg-5506 For The Treatment Of Individuals With Becker Muscular Dystrophy (Bmd)\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-08-16 21:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>Aug 16 (Reuters) - Edgewise Therapeutics Inc   :</p><p>   * EDGEWISE RECEIVES U.S. FDA FAST TRACK DESIGNATION FOR EDG-5506 FOR THE TREATMENT OF INDIVIDUALS WITH BECKER MUSCULAR DYSTROPHY <a href=\"https://laohu8.com/S/BMD.UK\">$(BMD.UK)$</a></p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"EWTX":"Edgewise Therapeutics, Inc."},"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2159221951","content_text":"Aug 16 (Reuters) - Edgewise Therapeutics Inc   :   * EDGEWISE RECEIVES U.S. FDA FAST TRACK DESIGNATION FOR EDG-5506 FOR THE TREATMENT OF INDIVIDUALS WITH BECKER MUSCULAR DYSTROPHY $(BMD.UK)$Source text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":1,"commentSize":1,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}